J. Kevin Buchi
Non-Executive Director
pharmaceutical
Benitec Biopharma
Australia
Biography
Mr. Buchi currently serves as the CEO of TetraLogic Pharmaceuticals a public U.S. Biotechnology company. Prioir to that, Kevin served as Chief Executive Officer (‘CEO’) of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (‘Teva’) in October 2011. After the acquisition he served as Corporate Vice President, Global Branded Products of Teva. Kevin joined Cephalon, Inc. in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO. Other Current Directorships of Listed Companies Tetralogic Pharmaceuticals Corporation Former Directorships of Listed Companies in last three years Stemline Therapeutics, Inc., Forward Pharma A/S, Alexza Pharmaceuticals and Epirus Biopharmaceuticals, Inc.
Research Interest
Mr. Buchi currently serves as the CEO of TetraLogic Pharmaceuticals a public U.S. Biotechnology company. Prioir to that, Kevin served as Chief Executive Officer (‘CEO’) of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (‘Teva’) in October 2011. After the acquisition he served as Corporate Vice President, Global Branded Products of Teva. Kevin joined Cephalon, Inc. in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO. Other Current Directorships of Listed Companies Tetralogic Pharmaceuticals Corporation Former Directorships of Listed Companies in last three years Stemline Therapeutics, Inc., Forward Pharma A/S, Alexza Pharmaceuticals and Epirus Biopharmaceuticals, Inc.
